Atossa Therapeutics Files 2024 10-K
Ticker: ATOS · Form: 10-K · Filed: Mar 25, 2025 · CIK: 1488039
Sentiment: neutral
Topics: 10-K, pharmaceutical, financials
TL;DR
Atossa dropped its 2024 10-K. Check financials & stock plans.
AI Summary
Atossa Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 25, 2025. The report details the company's financial performance and business operations, including information on its stock incentive plans and warrant agreements. The company is based in Seattle, WA, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with a comprehensive overview of Atossa Therapeutics' financial health and strategic direction for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Atossa Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K)
- 2025-03-25 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- ATOSSA THERAPEUTICS, INC. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-03-25 (date) — Filing Date
- SEATTLE, WA (location) — Business Address
- 2834 (industry_code) — Standard Industrial Classification
- 0000950170-25-044099 (accession_number) — SEC Filing Accession Number
FAQ
What is the primary business of Atossa Therapeutics, Inc.?
Atossa Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.
When did Atossa Therapeutics, Inc. file its 10-K report?
The 10-K report was filed on March 25, 2025.
What is the fiscal year end for the reported 10-K?
The fiscal year end for the reported 10-K is December 31, 2024.
Where is Atossa Therapeutics, Inc. located?
Atossa Therapeutics, Inc. is located in Seattle, WA.
What is the SEC file number for this 10-K filing?
The SEC file number for this 10-K filing is 001-35610.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 25, 2025 regarding ATOSSA THERAPEUTICS, INC. (ATOS).